Laurie Barclay, MD July 26, 2002
Although niacin has long been relatively contraindicated in type 2 diabetes due to its adverse effects on glucose control, a report in the July 22 issue of the Archives of Internal Medicine suggests that once-daily extended release niacin was well tolerated and effective for improving lipid levels in type 2 diabetics. However, the higher dose did significantly worsen glycemic control compared with placebo.
“Extended-release niacin may be considered as therapy in combination with statins, or in some cases, without statins, in the management of dyslipidemia associated with type 2 diabetes,” write Scott M. Grundy, MD, PhD, of the University of Texas Southwestern Medical Center in Dallas, and colleagues from the Diabetes Multicenter Research Group.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!